TAE Life Sciences Secures $30M in Initial B Round Phase to Accelerate Development of Unique Boron Delivery Drugs for Novel Cancer Treatment

June 2nd, 2020 Novel Small Molecule and Antibody Conjugate Approaches Expected to Enable Broad Adoption of Boron Neutron Capture Therapy  FOOTHILL RANCH, Calif., June 2, 2020 -- TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), announced the launch of...